NYLIM
ALXO icon

New York Life Investment Management’s ALX Oncology ALXO Stock Holding History

New York Life Investment Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-33,562
Closed -$378K – 1207
2022
Q4 		$378K Buy
33,562
+3,781
+13% +$42.5K ﹤0.01% 1065
2022
Q3 		$285K Buy
29,781
+2,187
+8% +$25.5K ﹤0.01% 1117
2022
Q2 		$223K Buy
+27,594
New +$300K ﹤0.01% 1216

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

New York Life Investment Management's ALXO Position: Q1 2023 in Review

New York Life Investment Management sold out of ALX Oncology (ALXO) in Q1 2023, closing a stake of 33,562 shares — an estimated $378K sold.

New York Life Investment Management first reported a position in ALXO in Q2 2022 and held it in 3 quarters. The position peaked at $378K in Q4 2022. 86 funds tracked by Wall St. Rank hold ALXO as of Q1 2023.

  • New York Life Investment Management reported no remaining ALX Oncology position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 33,562 ALX Oncology shares in Q1 2023, an estimated $378K.
  • New York Life Investment Management first reported a position in ALX Oncology in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's ALX Oncology position peaked at $378K in Q4 2022.
  • 86 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.